New therapeutic targets for human placental angiogenesis diseases
A large number of publications have described impaired angiogenesis and vasculogenesis present in the feto-placental circulation after pregnancy diseases such as pre-eclamptic pregnancies, gestational diabetes, and intrauterine growth restriction, among others. Results suggest impaired secretion and...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Online |
| Idioma: | anglès |
| Publicat: |
Frontiers Media SA
2021
|
| Matèries: | |
| Accés en línia: | 18712 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869528551381794816 |
|---|---|
| author | Carlos Alonso Escudero |
| author_browse | Carlos Alonso Escudero |
| author_facet | Carlos Alonso Escudero |
| author_sort | Carlos Alonso Escudero |
| collection | Directory of Open Access Books |
| description | A large number of publications have described impaired angiogenesis and vasculogenesis present in the feto-placental circulation after pregnancy diseases such as pre-eclamptic pregnancies, gestational diabetes, and intrauterine growth restriction, among others. Results suggest impaired secretion and activity of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), adenosine and nitric oxide, associates with compromised secretion and activity of anti-angiogenic factors such as soluble receptor of VEGF (sFlt-1), thrombospondin 2, endostatin among others. More recent evidences include the participation of endothelial progenitor cells (EPC), which circulating number is reduced infeto-placental circulation in pregnancies such as pre-eclampsia. Despite this knowledge, therapies for placental angiogenesis recovery during pathological pregnancies are far to be tested. However, from the cardiovascular field, it has been described the administration of EPC, alone or used as gene-transfer therapy; or it has been described the potential role of statins (HMGCoA inhibitors), or angiotensin-converter enzyme (ACE) inhibitors for enhancing angiogenesis. Finally, feto-placental tissue is an exceptional source of progenitor and stem cells, which could be used for treated other human diseases such as stroke, myocardial infarction, hypertension, or even cancer. In this research topic, authors highlight physiopatological and clinical importance of the impaired placental angiogenesis, and suggest potential targets for developing innovative therapies. |
| format | Online |
| id | doab-20.500.12854ir-54618 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-546182024-04-01T14:15:03Z New therapeutic targets for human placental angiogenesis diseases Carlos Alonso Escudero RM1-950 Q1-390 Angiogenesis Placenta therapy fetal programming Pregnancy Diseases thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology A large number of publications have described impaired angiogenesis and vasculogenesis present in the feto-placental circulation after pregnancy diseases such as pre-eclamptic pregnancies, gestational diabetes, and intrauterine growth restriction, among others. Results suggest impaired secretion and activity of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), adenosine and nitric oxide, associates with compromised secretion and activity of anti-angiogenic factors such as soluble receptor of VEGF (sFlt-1), thrombospondin 2, endostatin among others. More recent evidences include the participation of endothelial progenitor cells (EPC), which circulating number is reduced infeto-placental circulation in pregnancies such as pre-eclampsia. Despite this knowledge, therapies for placental angiogenesis recovery during pathological pregnancies are far to be tested. However, from the cardiovascular field, it has been described the administration of EPC, alone or used as gene-transfer therapy; or it has been described the potential role of statins (HMGCoA inhibitors), or angiotensin-converter enzyme (ACE) inhibitors for enhancing angiogenesis. Finally, feto-placental tissue is an exceptional source of progenitor and stem cells, which could be used for treated other human diseases such as stroke, myocardial infarction, hypertension, or even cancer. In this research topic, authors highlight physiopatological and clinical importance of the impaired placental angiogenesis, and suggest potential targets for developing innovative therapies. 2021-02-11T20:56:56Z 2021-02-11T20:56:56Z 2016-03-10 08:14:32 2015 book 18712 16648714 9782889194612 https://directory.doabooks.org/handle/20.500.12854/54618 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/New_therapeutic_targets_for_human_placental_angiogenesis_diseases/496 http://journal.frontiersin.org/researchtopic/1892/new-therapeutic-targets-for-human-placental-angiogenesis-diseases Frontiers Media SA 10.3389/978-2-88919-461-2 10.3389/978-2-88919-461-2 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889194612 113 open access |
| spellingShingle | RM1-950 Q1-390 Angiogenesis Placenta therapy fetal programming Pregnancy Diseases thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology Carlos Alonso Escudero New therapeutic targets for human placental angiogenesis diseases |
| title | New therapeutic targets for human placental angiogenesis diseases |
| title_full | New therapeutic targets for human placental angiogenesis diseases |
| title_fullStr | New therapeutic targets for human placental angiogenesis diseases |
| title_full_unstemmed | New therapeutic targets for human placental angiogenesis diseases |
| title_short | New therapeutic targets for human placental angiogenesis diseases |
| title_sort | new therapeutic targets for human placental angiogenesis diseases |
| topic | RM1-950 Q1-390 Angiogenesis Placenta therapy fetal programming Pregnancy Diseases thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| topic_facet | RM1-950 Q1-390 Angiogenesis Placenta therapy fetal programming Pregnancy Diseases thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| url | 18712 |
| work_keys_str_mv | AT carlosalonsoescudero newtherapeutictargetsforhumanplacentalangiogenesisdiseases |